| ELIXAEvaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) | Lixisenatide Cardiovascular disease, Type 2 diabetes | — | Ph 3 | Completed | 829 | Feb 2015 | 12 | results |
| LixiLan-OEfficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 273 | Jun 2015 | 8 | results |
| LixiLan-LEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 236 | Jul 2015 | 10 | results |
| GetGoal-Duo-2Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 199 | Dec 2014 | 3 | results |
| GETGOAL-PGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 150 | Jun 2011 | 1 | results |
| GetGoal-Duo124-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 140 | Aug 2011 | 6 | results |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 124 | May 2018 | 5 | results |
| LIXILAN JP-LEfficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 122 | Oct 2018 | 1 | |
| LIXILAN JP-O2Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 113 | Mar 2018 | 1 | |
| NCT0097693724-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years | Lixisenatide Obesity / overweight, Type 2 diabetes | BMI ≤50 | Ph 3 | Completed | 92 | Mar 2011 | — | results |
| LixiLan-DEfficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents | Lixisenatide Type 2 diabetes | HbA1c 7.5-10% | Ph 3 | Terminated | 85 | Jan 2019 | — | results |
| GetGoal-OEfficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients | Lixisenatide Type 2 diabetes | Age ≥70 | Ph 3 | Completed | 83 | Feb 2015 | 2 | results |
| NCT01517412Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 82 | May 2013 | 1 | results |
| Lixilan-O-APEvaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 79 | Mar 2021 | 2 | |
| NCT01476475Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients | Lixisenatide Type 2 diabetes | — | Ph 2 | Completed | 70 | Dec 2012 | 1 | results |
| LIRA-LIXI™Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes | Liraglutide, Lixisenatide Type 2 diabetes | BMI ≥20 | Ph 4 | Completed | 61 | Nov 2014 | 2 | results |
| LIXILAN JP-O1Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 61 | May 2018 | 1 | |
| NCT05413369iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) | Lixisenatide Type 2 diabetes | BMI ≤40 | Ph 3 | Completed | 60 | Oct 2023 | — | results |
| NCT01632163Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 51 | May 2015 | 2 | |
| Lixilan-L-CNComparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 45 | Dec 2020 | 3 | |
| GetGoal-M-AsiaEfficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 35 | Dec 2011 | 2 | results |
| LixilanOne CANStudy Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) | Lixisenatide Type 2 diabetes | BMI 20-40 | Ph 3 | Completed | 32 | Oct 2020 | 2 | |
| NCT01960179Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 30 | Mar 2015 | — | |
| NCT01940965Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 27 | Jul 2015 | — | |
| NCT02200991Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine | Lixisenatide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Completed | 20 | Nov 2015 | 1 | |
| LixiParkStudy to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease | Lixisenatide Parkinson's disease | — | Ph 2 | Completed | 20 | Apr 2021 | 1 | |
| GETGOAL-XGLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Exenatide, GLP-1 / incretin class catch-all, Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 18 | Nov 2010 | 2 | results |
| Soli-CGMEffect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus | Lixisenatide Type 2 diabetes | HbA1c 9-13% | Ph 4 | Completed | 18 | Mar 2023 | — | results |
| GETGOAL-MGLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 16 | Mar 2011 | 4 | results |
| GETGOAL-SGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 16 | Jan 2011 | 4 | results |
| LixiRamSafety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan | Lixisenatide Type 2 diabetes | — | Ph 4 | Completed | 16 | Aug 2017 | 2 | |
| GETGOAL-LGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 15 | Feb 2011 | 4 | results |
| GETGOAL-F1GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 15 | Jan 2011 | 3 | results |
| NCT03529123Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) | Lixisenatide Type 2 diabetes | BMI 19-40 | Ph 3 | Completed | 13 | Nov 2019 | — | |
| GETGOAL-MONOGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 12 | Dec 2009 | 2 | results |
| NCT02803918A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) | Lixisenatide Obesity / overweight, Type 2 diabetes | HbA1c 6.5-11% | Ph 1 | Completed | 11 | Jan 2020 | 1 | |
| SEVERALSEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥30 | — | Completed | 11 | Nov 2023 | 14 | |
| NCT06716424A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus | Lixisenatide Type 2 diabetes | BMI ≥25 | Ph 4 | Active, not recruiting | 10 | Jun 2026 | — | |
| NCT01596504Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin | Liraglutide, Lixisenatide Type 2 diabetes | BMI 20-40 | Ph 2 | Completed | 8 | Jul 2013 | 1 | results |
| REMIT-iGLRemission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi | Lixisenatide Type 2 diabetes | HbA1c 6.5-9.5% | Ph 3 | Completed | 8 | Jun 2019 | — | |
| NCT00299871Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus | Lixisenatide Type 2 diabetes | BMI 25-40 | Ph 2 | Completed | 7 | Aug 2007 | 1 | |
| NCT01175473Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes | Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 2 | Completed | 7 | Nov 2010 | 1 | results |
| GLP-1REWINGLP-1 REceptor Agonists and Real World EvIdeNce | Dulaglutide, Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | — | — | Unknown | 6 | Feb 2019 | 6 | |
| NCT01572649Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes | Lixisenatide Type 2 diabetes | HbA1c 7-10% | Ph 1 | Completed | 6 | Mar 2014 | — | |
| GETGOAL-L-ASIAGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 4 | Jun 2010 | 3 | results |
| VARIATION 2 SAThe Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians | Lixisenatide Type 2 diabetes | BMI 20-40 | Ph 4 | Completed | 3 | Nov 2019 | 22 | |
| NCT02231658Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion | Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 1 | Terminated | 2 | Jul 2018 | 1 | |
| NCT01910194Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying | Lixisenatide Type 2 diabetes | — | Ph 2 | Completed | 2 | Oct 2014 | — | |
| CER-4-T2DComparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | — | — | Active, not recruiting | 1 | May 2026 | — | |
| NCT06449235Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide, Semaglutide Type 2 diabetes | HbA1c 7-10% | Ph 4 | Not yet recruiting | 1 | Apr 2025 | — | |
| China Soli-CGMiGlarLixi CGM Study in Chinese T2D Individuals After OADs | Lixisenatide Type 2 diabetes | BMI 20-40 | Ph 4 | Recruiting | 1 | Sep 2026 | — | |
| NCT07117240Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes | Lixisenatide Diabetes (other / unspecified), Type 2 diabetes | — | Ph 4 | By invitation | 1 | Feb 2028 | — | |
| DASH-CKMHUsing Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) | Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide Metabolic syndrome | — | — | Active, not recruiting | 1 | Jun 2029 | — | |
| NCT07274644Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease | Lixisenatide MASH / NAFLD / liver fibrosis, Type 2 diabetes | BMI 25-35 | Ph 4 | By invitation | 1 | May 2026 | — | |
| GETGOAL-MONOGLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS) | Lixisenatide Type 2 diabetes | — | Ph 3 | Completed | 1 | Jan 2011 | 1 | results |
| NCT01146678Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1 | Lixisenatide Type 1 diabetes | HbA1c ≤9% | Ph 1 | Completed | 1 | Sep 2010 | — | |
| NCT02020629Study on Lixisenatide and Counterregulation to Hypoglycemia | Lixisenatide Type 2 diabetes | HbA1c ≤10% | Ph 4 | Completed | 1 | Aug 2014 | 1 | |
| NCT02049034Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes | Lixisenatide Type 2 diabetes | BMI 27-40 | Ph 4 | Completed | 1 | Jan 2016 | 1 | |
| LixiBITFeasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin | Lixisenatide Type 2 diabetes | HbA1c 7-10% | Ph 3 | Completed | 1 | Jul 2015 | 1 | results |
| NCT02244164Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. | Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | BMI 20-45 | Not applicable | Terminated | 1 | Feb 2023 | 4 | |
| ELIXIRSEffect of LIXIsenatide on the Renal System | Lixisenatide Type 2 diabetes | BMI ≥25 | Ph 4 | Completed | 1 | Apr 2016 | 1 | |
| LixiDrug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People | Lixisenatide Healthy volunteers, Type 2 diabetes | BMI 19-30 | Ph 1/2 | Unknown | 1 | Apr 2016 | 38 | |
| EGLIPAThe Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) | Exenatide, Liraglutide, Lixisenatide Type 2 diabetes | — | Ph 4 | Unknown | 1 | Jul 2015 | 3 | |
| NCT02713477Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus | Lixisenatide Type 2 diabetes | BMI ≤35 | Ph 1 | Completed | 1 | Jun 2016 | 1 | |
| NCT02767596Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog | Lixisenatide Type 2 diabetes | — | Ph 4 | Terminated | 1 | Feb 2017 | — | |
| NCT03492580A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease | Albiglutide, Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Cardiovascular disease, Type 2 diabetes | Established CVD | — | Completed | 1 | Apr 2018 | — | |
| Lixibrain01Effects of Insulin Glargine and Lixisenatide on the Brain | Lixisenatide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 4 | Terminated | 1 | Jun 2020 | — | |
| NCT04184947Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists | Dulaglutide, Exenatide, GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | — | — | Completed | 1 | Dec 2018 | 1 | |
| BEYONDDurability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) | GLP-1 / incretin class catch-all, Liraglutide, Lixisenatide Type 2 diabetes | HbA1c ≥7.5% | Ph 4 | Completed | 1 | Sep 2020 | 3 | |
| IDEALINSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi | Lixisenatide Type 2 diabetes | — | Ph 4 | Unknown | 1 | Jan 2023 | 1 | |
| RESTORELixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2 | Lixisenatide Type 2 diabetes | BMI 25-35 | Ph 1 | Completed | 1 | Aug 2009 | — | |
| NCT02745470Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain | Lixisenatide Obesity / overweight, Type 2 diabetes | BMI ≤23 | Not applicable | Completed | 1 | Dec 2016 | — | |
| NCT04893148Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes | Dulaglutide, Lixisenatide Type 2 diabetes | — | Ph 4 | Unknown | 1 | Dec 2021 | — | |
| NCT05591391The Efficacy of Mallya in Type 2 Diabetes Transiting From Oral Antidiabetic Drugs to iGlarLixi | Lixisenatide Type 2 diabetes | HbA1c ≥7% | Not applicable | Unknown | 1 | Jun 2025 | — | |
| NCT05804513The Effect of Lixisenatide on the Effect of Pituitary Hormones | Lixisenatide Healthy volunteers, Type 1 diabetes | HbA1c ≤8.5% | Ph 4 | Unknown | 1 | Oct 2023 | — | |
| NCT07307235Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents | Lixisenatide Type 2 diabetes | HbA1c 7.5-11% | Ph 4 | Not yet recruiting | 0 | Jun 2027 | — | |
| NCT02274740Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients | Lixisenatide Dyslipidemia, Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 2 | Terminated | 0 | Aug 2015 | — | |
| Px-LixiThe Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects | Lixisenatide Diabetes (other / unspecified), Healthy volunteers | Healthy volunteers | Not applicable | Completed | 0 | Jul 2016 | 1 | |
| NCT07173712Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | Lixisenatide Type 2 diabetes | BMI 20-35 | Ph 4 | Not yet recruiting | 0 | Jun 2027 | — | |
